Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Conister011on Sep 24, 2019 8:26pm

168 Views

Post# 30161185

Pause

Not sure what's going on on this board now but if your new try to avoid the noise and stick to the facts. Kly is a trial company. It has had very encouraging success with its phase 2 trials and will be headed in phase 3 in the near future. Thieves not a trade, it's an investment. If you watch it daily and read all the post here you will lose your mind:). Buy what you can afford and come back periodically to check in. If a partnership or buyout happens, my belief, you will have a very successful trade on your hands. Do your own dd and relax. This should all unfold invite next couple of months. GLTA

Bullboard Posts

Eminent acquires promising Nevada gold project